Zacks Research Upgrades Barinthus Biotherapeutics (NASDAQ:BRNS) to Hold

Barinthus Biotherapeutics (NASDAQ:BRNS) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Stock Up 3.5%

BRNS stock opened at $0.73 on Wednesday. Barinthus Biotherapeutics has a twelve month low of $0.51 and a twelve month high of $1.83. The stock has a market capitalization of $29.87 million, a price-to-earnings ratio of -0.71 and a beta of -0.39. The firm’s fifty day simple moving average is $0.62 and its two-hundred day simple moving average is $0.63.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. As a group, equities research analysts expect that Barinthus Biotherapeutics will post -0.93 EPS for the current year.

Institutional Trading of Barinthus Biotherapeutics

A number of large investors have recently modified their holdings of BRNS. Baird Financial Group Inc. grew its stake in Barinthus Biotherapeutics by 108.2% in the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after purchasing an additional 100,000 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Barinthus Biotherapeutics by 115.8% during the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after purchasing an additional 76,800 shares during the period. Finally, Rangeley Capital LLC increased its holdings in Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after purchasing an additional 75,024 shares during the period. Hedge funds and other institutional investors own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.